Research
Cellular
GLP-1 receptor agonists are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits.
GLP-1 receptor agonists can be utilized in clinical practice for managing steatotic liver disease effectively.
StrongSupportsmedium confidence
They are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits.
Why this rating
Supported by clinical evidence from trials and studies.
Source
Review Article: The Evolving Role of <scp>GLP</scp> ‐1 Receptor Agonists in Gastroenterology Practice
Sydney Pomenti et al. · Alimentary Pharmacology & Therapeutics · 2025
DOI 10.1111/apt.70450
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →